Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (131-140 of 312) with videos related to

Pageof 32
Sort By:
BJU International|November 28, 2008
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerLaurence Klotz, Laurent Boccon-Gibod, Neal D Shore, et al.
The Oncologist|October 25, 2024
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT studyTomasz M Beer, Daniel J George, Neal D Shore, et al.
Future Oncology (London, England)|October 25, 2024
The TALAPRO-3 study design: a plain language summaryNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Urology Practice|June 15, 2023
The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 YearsAdam B Weiner, Adarsh Manjunath, Gary M Kirsh, et al.
Advances in Therapy|July 20, 2021
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP InhibitorsNeal D Shore, François Laliberté, Raluca Ionescu-Ittu, et al.
The Journal of Urology|August 23, 2017
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN TrialD Robert Siemens, Laurence Klotz, Axel Heidenreich, et al.
Prostate Cancer and Prostatic Diseases|March 27, 2025
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARKUgo De Giorgi, Stephen J Freedland, Antti Rannikko, et al.
The Lancet. Oncology|January 18, 2016
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 studyNeal D Shore, Simon Chowdhury, Arnauld Villers, et al.
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Therapeutic Advances in Urology|February 14, 2018
Pharmacokinetic and pharmacodynamic comparison of subcutaneous <i>versus</i> intramuscular leuprolide acetate formulations in male subjectsDaniel Saltzstein, Neal D Shore, Judd W Moul, et al.
Pageof 32

Showing results (131-140 of 312) with videos related to

Sort By:
Pageof 32
BJU International|November 28, 2008
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerLaurence Klotz, Laurent Boccon-Gibod, Neal D Shore, et al.
The Oncologist|October 25, 2024
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT studyTomasz M Beer, Daniel J George, Neal D Shore, et al.
Future Oncology (London, England)|October 25, 2024
The TALAPRO-3 study design: a plain language summaryNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Urology Practice|June 15, 2023
The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 YearsAdam B Weiner, Adarsh Manjunath, Gary M Kirsh, et al.
Advances in Therapy|July 20, 2021
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP InhibitorsNeal D Shore, François Laliberté, Raluca Ionescu-Ittu, et al.
The Journal of Urology|August 23, 2017
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN TrialD Robert Siemens, Laurence Klotz, Axel Heidenreich, et al.
Prostate Cancer and Prostatic Diseases|March 27, 2025
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARKUgo De Giorgi, Stephen J Freedland, Antti Rannikko, et al.
The Lancet. Oncology|January 18, 2016
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 studyNeal D Shore, Simon Chowdhury, Arnauld Villers, et al.
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Therapeutic Advances in Urology|February 14, 2018
Pharmacokinetic and pharmacodynamic comparison of subcutaneous <i>versus</i> intramuscular leuprolide acetate formulations in male subjectsDaniel Saltzstein, Neal D Shore, Judd W Moul, et al.
Pageof 32